Literature DB >> 14977565

Adeno-associated viral vector-mediated ApoE expression in Alzheimer's disease mice: low CNS immune response, long-term expression, and astrocyte specificity.

Xuan Feng1, Fernette F Eide, Hong Jiang, Anthony T Reder.   

Abstract

Recombinant Adenovirus and Adeno-associated virus (AAV) are highly effective vehicles for gene transfer into CNS cells. However, the duration of gene expression and the cytotoxicity to cells are quite different between these viral approaches. We initially investigated these distinctions by stereotaxically injecting both Adenovirus vector and AAV vectors expressing reporter genes into mouse hippocampus. The adenovirus vector induced a pronounced immune response with a marked increase in CD45 and MHC class I protein expression and transgene expression was shorter than six weeks. In contrast, with the AAV vector there was lower expression of CD45 and MHC class I immune activation markers, and longer expression of reporter gene (up to 12 months). To study the roles of human Apolipoprotein E (ApoE) alleles in the pathogenesis of Alzheimer's disease and other CNS diseases, we generated recombinant AAV-apoE alleles driven by the GFAP promoter and expressed them in the mouse brain of Alzheimer's disease mouse. High level ApoE expressions in mouse brain lasted for 12 months, and ApoE was specifically expressed in astrocytes. We demonstrate that AAV-GFAP-ApoE is valuable in studying the pathogenesis and in gene therapy for Alzheimer's disease and other CNS diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14977565     DOI: 10.2741/1323

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  11 in total

1.  Specific disruption of astrocytic Ca2+ signaling pathway in vivo by adeno-associated viral transduction.

Authors:  Y Xie; T Wang; G Y Sun; S Ding
Journal:  Neuroscience       Date:  2010-08-22       Impact factor: 3.590

2.  Tropism and toxicity of adeno-associated viral vector serotypes 1, 2, 5, 6, 7, 8, and 9 in rat neurons and glia in vitro.

Authors:  Douglas B Howard; Kathleen Powers; Yun Wang; Brandon K Harvey
Journal:  Virology       Date:  2007-11-26       Impact factor: 3.616

Review 3.  Adeno-associated virus-based Alzheimer's disease mouse models and potential new therapeutic avenues.

Authors:  Lars M Ittner; Matthias Klugmann; Yazi D Ke
Journal:  Br J Pharmacol       Date:  2019-04-23       Impact factor: 8.739

4.  Prohibitin viral gene transfer protects hippocampal CA1 neurons from ischemia and ameliorates postischemic hippocampal dysfunction.

Authors:  Hitomi Kurinami; Munehisa Shimamura; Tao Ma; Liping Qian; Kenzo Koizumi; Laibaik Park; Eric Klann; Giovanni Manfredi; Costantino Iadecola; Ping Zhou
Journal:  Stroke       Date:  2014-03-11       Impact factor: 7.914

Review 5.  Primate models of schizophrenia: future possibilities.

Authors:  Arthur A Simen; Ralph DiLeone; Amy F T Arnsten
Journal:  Prog Brain Res       Date:  2009-11-20       Impact factor: 2.453

Review 6.  Novel aspects of prions, their receptor molecules, and innovative approaches for TSE therapy.

Authors:  Karen Vana; Chantal Zuber; Daphne Nikles; Stefan Weiss
Journal:  Cell Mol Neurobiol       Date:  2006-12-07       Impact factor: 5.046

7.  Insights into neurogenesis and aging: potential therapy for degenerative disease?

Authors:  Robert A Marr; Rosanne M Thomas; Daniel A Peterson
Journal:  Future Neurol       Date:  2010-07-01

8.  Lack of humoral immune response to the tetracycline (Tet) activator in rats injected intracranially with Tet-off rAAV vectors.

Authors:  Y Han; Q A Chang; T Virag; N C West; D George; M G Castro; M C Bohn
Journal:  Gene Ther       Date:  2010-02-18       Impact factor: 5.250

9.  Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS.

Authors:  Nicholas M Kanaan; Rhyomi C Sellnow; Sanford L Boye; Ben Coberly; Antonette Bennett; Mavis Agbandje-McKenna; Caryl E Sortwell; William W Hauswirth; Shannon E Boye; Fredric P Manfredsson
Journal:  Mol Ther Nucleic Acids       Date:  2017-06-21       Impact factor: 8.886

10.  Prophylaxis and treatment of Alzheimer's disease by delivery of an adeno-associated virus encoding a monoclonal antibody targeting the amyloid Beta protein.

Authors:  Masaru Shimada; Shinya Abe; Toru Takahashi; Kazumasa Shiozaki; Mitsue Okuda; Hiroaki Mizukami; Dennis M Klinman; Keiya Ozawa; Kenji Okuda
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.